Prednisolone suppresses the immunostimulatory effects of 27-hydroxycholesterol
EXPERIMENTAL AND THERAPEUTIC MEDICINE
Authors: Kim, Bo-Young; Son, Yonghae; Kim, Min Su; Kim, Koanhoi
Abstract
In cholesterol-fed rabbits, site-specific targeting of prednisolone nanoparticles results in significantly reduced neo-intimal inflammation with a decreased infiltration of monocytes/macrophages. To understand the molecular mechanisms underlying this, the current study investigated whether prednisolone affects the immune attributes of 27-hydroxycholesterol (27OHChol), the major oxidized cholesterol molecule in circulation and tissue, in human (THP-1) monocyte/macrophage cells. THP-1 cells were exposed to 27OHChol in the presence of prednisolone followed by evaluation of inflammatory molecules at mRNA and protein levels by quantitative PCR, western blotting, ELISA and flow cytometry. The results revealed that prednisolone suppressed the 27OHChol-mediated expression of various macrophage (M)1 markers, including chemokine ligand 2, C-X-C chemokine motif 10, tumor necrosis factor-alpha and CD80. Treatment also impaired the 27OHCHol-enhanced migration of monocytic cells, downregulated the 27OHChol-induced cell surface expression of CD14 and inhibited the release of soluble CD14 comparable with a weakened lipopolysaccharide response. Furthermore, prednisolone suppressed the 27OHChol-induced expression of matrix metalloproteinase 9 at the transcriptional and protein level, as well as the phosphorylation of the p65 subunit. Prednisolone increased the transcription of CD163 and CD206 genes, and augmented the 27OHChol-induced transcription of CD163 without upregulating the 27OHChol-induced surface protein level of the gene. The results indicated that prednisolone inhibited the polarization of monocytes/macrophages towards the M1 phenotype, which that the immunostimulatory effects of 27OHCHol were being regulated and the immune responses in conditions that were rich in oxygenated cholesterol molecules were being modulated.
Effect of Glycine on BV-2 Microglial Cells Treated with Interferon-gamma and Lipopolysaccharide
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Authors: Egger, Florentina; Jakab, Martin; Fuchs, Julia; Oberascher, Karin; Brachtl, Gabriele; Ritter, Markus; Kerschbaum, Hubert H.; Gaisberger, Martin
Abstract
Microglia are first-line defense antigen-presenting phagocytes in the central nervous system. Activated microglial cells release pro-inflammatory cytokines and can trigger an oxidative burst. The amino acid glycine exerts anti-inflammatory, immunomodulatory and cytoprotective effects and influences cell volume regulation. This study aimed to investigate the role of glycine in the modulation of inflammatory processes in mouse BV-2 microglial cells. Inflammatory stress was induced by lipopolysaccharide/interferon-gamma (LPS/IFN-gamma) treatment for 24 h in the absence or presence of 1 or 5 mM glycine. Cells were analyzed by flow cytometry for cell volume, side scatter, apoptosis/necrosis and expression of activation-specific surface markers. Apoptosis progression was monitored by life cell imaging. Reduced glutathione/oxidized glutathione (GSH/GSSG) ratios and release of the pro-inflammatory cytokines IL-6 and TNF-alpha were measured using luminescence-based assays and ELISA, respectively. We found that LPS/IFN-gamma-induced apoptosis was decreased and the fraction of living cells was increased by glycine. Expression of the surface markers CD11b, CD54 and CD80 was dose-dependently increased, while IL-6 and TNF-alpha release was not altered compared to LPS/IFN-gamma-treated cells. We showed that in BV-2 microglial cells glycine improves viability and counteracts deleterious responses to LPS/IFN-gamma, which might be relevant in neurodegenerative processes associated with inflammation, like Alzheimer's or Parkinson's disease.